Drug Discovery

Sapience raises funding to advance cancer therapy programmes

Sapience Therapeutics has raised $41m in a Series B funding round to advance the pipeline of peptide therapeutics targeting protein-protein interactions.

PharmEnable, Denali Therapeutics partner for neurodegenerative disease drugs

AI drug discovery firm PharmEnable and biopharmaceutical company Denali Therapeutics have entered into a multi-target collaboration to accelerate drug discovery in neurodegenerative diseases.

Novartis’ Cosentyx gets CHMP positive opinion for use in childhood arthritic conditions

Novartis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Cosentyx (secukinumab) for usage either alone or in combination with methotrexate.

CBDepot

CBDepot produces high-quality natural cannabinoid ingredients and cannabinoid-enriched products for the industrial and consumer market.

BenevolentAI, DNDi begin joint AI research project on dengue

BenevolentAI and Drugs for Neglected Disease initiative (DNDi) have commenced a joint AI research project to address dengue.

Biocytogen, CtM Biotech partner to develop new antibody drugs

Biocytogen Pharmaceuticals and CtM Biotech have entered into a collaboration agreement to co-develop TCR-mimic antibody-based multi-specific T cell engagers targeting intracellular tumor-associated antigens.

Asahi Kasei Medical agrees to buy Bionova Scientific

Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.

Ardelyx amends license deal with Kyowa Kirin for tenapanor

Ardelyx and its Japanese collaboration partner Kyowa Kirin have amended their license agreement for tenapanor.

Harbour BioMed, AstraZeneca sign license deal for bispecific antibody

Biopharmaceutical firm Harbour BioMed (HBM) and AstraZeneca have entered into a global out-license agreement for CLDN18.2xCD3 bispecific antibody HBM7022.